Hemab Therapeutics Holdings, Inc. Common Stock
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a COAG research report →
Range $36 – $70
Price Chart
About the company
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies.
- CEO
- Benny Sorensen
- IPO
- 2026
- Employees
- 59
- HQ
- Cambridge, MA, US
Get TickerSpark's AI analysis on COAG
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.84B
- P/E
- -20.71
- PEG
- 0.16
- P/S
- 0.00
- P/B
- 4.26
- EV/EBITDA
- -16.50
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -73.56%
- ROIC
- -23.22%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-70,119,000
- Net Income
- $-63,913,000+0.0%
- EPS
- $-2.33+0.0%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $55.42
- 52W Low
- $23.00
- 50D MA
- $36.72
- 200D MA
- $37.26
- Beta
- 1.85
- RSI (14)
- 52
- Avg Volume
- 496.66K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Hemab reported a larger Q3 loss but highlighted a major milestone with the start of its first pivotal Phase III trial and encouraging early data across its bleeding-disorder pipeline.· November 10, 2026
- Hemab initiated SOLARA, its pivotal Phase III trial of sutacimig in Glanzmann thrombasthenia, and said this is its first pivotal trial and the first pivotal trial of a subcutaneous prophylactic treatment in the disease.
- The company also disclosed first clinical data for sutacimig in Factor VII deficiency and new preclinical menstrual-bleeding data for HMB-003, with more updates slated for ASH in December and EAHAD in February 2027.
- HMB-002 data at ISTH showed peak increases of about 2.5-fold in both von Willebrand Factor and Factor VIII, with 8 of 9 evaluable patients having zero treated bleeds in 28 days after dosing.
- Management said cash of $430.2 million should fund operations into 2029, giving the company runway as it moves deeper into late-stage development.
- The main debate point on the call was regulatory: FDA recommended considering a randomized trial for SOLARA, but Hemab chose a single-arm design after discussing feasibility and variability in this rare disease.
Cash, cash equivalents and marketable securities were $430.2 million as of September 30, down from $457.5 million as of June 30. Q3 2026 R&D expense was $24.6 million versus $14.6 million in Q3 2025, and G&A expense was $5.1 million versus $2.5 million last year. Net loss for Q3 2026 was $27.3 million, or $0.58 per share, compared with $17.1 million in the prior-year quarter. Management said current cash is expected to fund operations into 2029. On guidance, Hemab expects updated Factor VII deficiency data and HMB-003 data at ASH in December, initial HMB-002 data at EAHAD in February, and initial Phase I data for HMB-003 in mid-2027.
Benny Sorensen framed the quarter as a turning point, saying Hemab is moving from IPO momentum into late-stage development with SOLARA and a broader commercial build-out. His tone was highly confident and patient-focused, emphasizing that the company is trying to reimagine care for rare bleeding disorders and that prevention can become the standard of care. He repeatedly stressed that the science, clinical strategy, and regulatory path are aligned with the realities of rare-disease development.
Mads Behrndt-Eriksen kept the financial update brief: cash, cash equivalents and marketable securities were $430.2 million at quarter-end, down from $457.5 million at June 30, and he said that balance should support operations into 2029. R&D rose to $24.6 million from $14.6 million a year ago, driven mainly by clinical advancement and higher personnel costs, while G&A increased to $5.1 million from $2.5 million. Net loss widened to $27.3 million, or $0.58 per share, from $17.1 million last year.
Analysts focused heavily on whether the FDA’s suggestion of a randomized trial for SOLARA signaled regulatory risk. Management said the agency recommended considering randomization but also acknowledged feasibility concerns in Glanzmann thrombasthenia, and Hemab argued its single-arm, intra-patient design is common in bleeding-disorder registrational programs. Questions also centered on the Phase III eligibility and cardiovascular-risk safeguards; Benny said the company had received praise for its safety monitoring plan and that there were no surprises. For HMB-002, analysts asked about what to watch in the February data; management pointed to additional single- and multiple-ascending-dose readouts, aiming for roughly 2- to 3-fold biomarker increases and more than 50% bleed reduction.
The call reinforced that Hemab has multiple shots on goal, with clinical catalysts across all three programs over the next several quarters. Management highlighted encouraging biomarker and bleed-reduction signals for HMB-002, early Factor VII data that may support a broader investment case, and a pivotal Glanzmann program now underway. The company also has a long cash runway into 2029, reducing near-term financing pressure.
The biggest risk flagged was regulatory and study-design uncertainty around SOLARA, since the FDA recommended considering a randomized controlled trial and Hemab is proceeding with a single-arm design. Safety is also a watch item: management disclosed three Grade 2 thromboembolic events in higher-exposure Glanzmann cohorts, which helped shape the lower-dose Phase III regimen. On the financial side, spending is rising as programs advance, with both R&D and G&A higher year over year and no commercial revenue discussed.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 38.4%
- Shares Outstanding
- 46.73M
- Float Shares
- 17.96M
of shares held by institutions
57 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Ra Capital Management, L.P. | 7.81M | ▲ 7.81M |
| Novo Holdings A/S | 4.18M | ▲ 4.18M |
| Fmr LLC | 3.72M | ▲ 24.76K |
| Deep Track Capital, LP | 3.60M | ▲ 3.60M |
| Capital International Investors | 3.60M | ▼ 2.41K |
| Siren, L.L.C. | 2.37M | ▲ 279.40K |
| Avoro Capital Advisors LLC | 1.93M | ▲ 1.93M |
| Bain Capital Life Sciences Investors, LLC | 1.65M | ▲ 1.65M |
| Jpmorgan Chase & Co | 932.86K | ▼ 219.56K |
| State Street Corp | 927.25K | ▲ 850.35K |
| Vanguard Capital Management LLC | 780.76K | ▲ 780.76K |
| Price T Rowe Associates Inc | 746.04K | ▲ 746.04K |
Held by 180 ETFs
Biggest fund positions in COAG by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 24, 26 | Walbert Keli | other | 36,000 |
| Sep 24, 26 | Walbert Keli | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our COAG coverage
Recent articles, reports, and earnings notes.
No research on COAG yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate COAG report →Hemab Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com · Nov 11
Hemab Therapeutics Holdings, Inc. (COAG) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 10
What Hemab Therapeutics (COAG) Said on Its Q3 Earnings Call
marketbeat.com · Nov 10
Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com · Nov 10
Hemab Therapeutics Initiates SOLARA, a Pivotal Phase 3 Trial of Sutacimig in Glanzmann Thrombasthenia
globenewswire.com · Nov 9
Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and Exposition
globenewswire.com · Nov 4
Hemab Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 10, 2026
globenewswire.com · Nov 3
Hemab Therapeutics (NASDAQ:COAG) Shares Gap Down – Here’s What Happened
defenseworld.net · Oct 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.